JP2002167368A - Alkyl group-substituted dendrimer and method for preparing the same - Google Patents

Alkyl group-substituted dendrimer and method for preparing the same

Info

Publication number
JP2002167368A
JP2002167368A JP2000366555A JP2000366555A JP2002167368A JP 2002167368 A JP2002167368 A JP 2002167368A JP 2000366555 A JP2000366555 A JP 2000366555A JP 2000366555 A JP2000366555 A JP 2000366555A JP 2002167368 A JP2002167368 A JP 2002167368A
Authority
JP
Japan
Prior art keywords
dendrimer
substituted
alkyl
alkyl group
following formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000366555A
Other languages
Japanese (ja)
Inventor
Naoki Sadayori
直樹 貞頼
Shu Mochizuki
周 望月
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Priority to JP2000366555A priority Critical patent/JP2002167368A/en
Publication of JP2002167368A publication Critical patent/JP2002167368A/en
Pending legal-status Critical Current

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide an alkyl group-substituted dendrimer which is an amphiphilc molecule and is suitable as an coating agent for modifying the surface of material having polar functional groups. SOLUTION: This alkyl group-substituted dendrimer is represented by the general formulas (Ia) or (Ib), (wherein, R means the general formula (II); n is an integer of 2 to 20).

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の背景】本発明は新規なアルキル置換デンドリマ
ーに関する。本発明のアルキル置換デンドリマーは両親
媒性分子であり、極性官能基を有する材料表面を変性す
るコーティング剤などとして用いることができる。
BACKGROUND OF THE INVENTION The present invention relates to novel alkyl-substituted dendrimers. The alkyl-substituted dendrimer of the present invention is an amphipathic molecule and can be used as a coating agent or the like for modifying the surface of a material having a polar functional group.

【0002】デンドリマーは高度に分岐した三次元構造
を有するポリマーであり、末端を機能性低分子で修飾す
ることにより、様々な機能を付与することが可能であ
り、鎖状のポリマーとは異なる性質を持つと考えられ
る。本発明のアルキル置換デンドリマーはコア部分と置
換基部分とが相溶しない両親媒性分子であり、これら各
部分の位置関係が対応する鎖状ポリマーとは異なる。本
発明のアルキル置換デンドリマーは表面処理剤として用
いることができる。表面処理による機能は主にアルキル
基部分の構造に由来し、例えば撥水機能や液晶配向機能
が得られる。表面処理剤としての機能はデンドリマー分
子の形状に特徴的なものである。例えば、デンドリマー
誘導体、直鎖誘導体(ポリ(エチレンイミン)誘導体)、低
分子誘導体を比較したとき、デンドリマー誘導体のみが
液晶配向処理剤の機能を示す。
[0002] Dendrimers are polymers having a highly branched three-dimensional structure, and can be imparted with various functions by modifying the terminal with a functional low-molecular-weight compound. It is thought to have. The alkyl-substituted dendrimer of the present invention is an amphipathic molecule in which the core portion and the substituent portion are incompatible, and the positional relationship between these portions is different from the corresponding linear polymer. The alkyl-substituted dendrimer of the present invention can be used as a surface treatment agent. The function of the surface treatment mainly comes from the structure of the alkyl group portion, and for example, a water repellent function and a liquid crystal alignment function can be obtained. The function as a surface treatment agent is characteristic of the shape of the dendrimer molecule. For example, when a dendrimer derivative, a linear derivative (poly (ethylene imine) derivative), and a low molecular weight derivative are compared, only the dendrimer derivative shows the function of the liquid crystal alignment treatment agent.

【0003】ポリ(プロピレンイミン)デンドリマーの末
端にアルキル置換基を結合したアルキル置換デンドリマ
ーとしてはMeijerらの例があるが、これは置換基とデン
ドリマーとの結合生成にアミド縮合を用いたものであ
る。これと異なり本発明は、Michael反応用いて非アミ
ド型アルキル置換デンドリマーを得る。
An example of an alkyl-substituted dendrimer in which an alkyl substituent is bonded to the terminal of a poly (propylene imine) dendrimer is disclosed by Meijer et al., Which uses amide condensation to form a bond between the substituent and the dendrimer. . In contrast, the present invention uses a Michael reaction to obtain non-amide type alkyl-substituted dendrimers.

【0004】[0004]

【発明の概要】即ち、本発明は、下式:SUMMARY OF THE INVENTION That is, the present invention provides a compound represented by the following formula:

【化9】 Embedded image

【0005】又は[0005] or

【化10】 Embedded image

【0006】(式中、Rは、(Where R is

【化11】 を意味し、nは2〜20の整数である。)で表されるア
ルキル置換デンドリマーを提供するものである。
Embedded image And n is an integer of 2 to 20. ) Is provided.

【0007】また、本発明は下式:Further, the present invention provides the following formula:

【化12】 Embedded image

【0008】又は[0008] or

【化13】 Embedded image

【0009】で表される多官能アミン化合物と下式:A polyfunctional amine compound represented by the following formula:

【化14】 (式中、nは前記に同じ。)で表されるアルキル置換アク
リル酸エステル誘導体を、有機溶剤中にて触媒の存在下
または非存在下で反応させることを特徴とするアルキル
置換デンドリマーの製造法に関する。
Embedded image Wherein n is the same as defined above, wherein the alkyl-substituted acrylate derivative is reacted in an organic solvent in the presence or absence of a catalyst. About.

【0010】[0010]

【発明の詳細な開示】本発明のアルキル置換デンドリマ
ーは多官能性アミン化合物をコアとする。かかるコアと
しては、ポリプロピレンイミンデンドリマーDAB−A
m−4,ポリ(プロピレンイミン)デンドリマー第1世代
(Poly(propyleneimine)Dendrimer,Generation1.0)(式
(IIIa))、DAB−Am−8,ポリ(プロピレンイミン)デ
ンドリマー第2世代(Poly(propyleneimine)Dendrimer,G
eneration2.0)(式(IIIb))(いずれもDSM社製)など
を用いることができる。これらの化合物はエチレンジア
ミンとアクリロニトリルを出発原料として合成すること
もできる。
DETAILED DESCRIPTION OF THE INVENTION The alkyl-substituted dendrimers of the present invention are based on a polyfunctional amine compound. Such cores include polypropylene imine dendrimer DAB-A
m-4, poly (propylene imine) dendrimer first generation
(Poly (propyleneimine) Dendrimer, Generation1.0)
(IIIa)), DAB-Am-8, poly (propyleneimine) dendrimer second generation (Poly (propyleneimine) Dendrimer, G
eneration 2.0) (formula (IIIb)) (all manufactured by DSM) can be used. These compounds can also be synthesized using ethylenediamine and acrylonitrile as starting materials.

【0011】多官能性アミン化合物であるポリプロピレ
ンイミンデンドリマーの末端は、アルキル置換アクリル
酸エステル誘導体により修飾する。アルキル置換アクリ
ル酸エステル誘導体としては、前記式(IV)で表される化
合物が用いられる。ここでnは2〜20、好ましくは6
〜20である。具体的な化合物としては、オクタデシル
アクリレート、ドデシルアクリレート、オクタデシルメ
タクリレート、ドデシルメタクリレートなどが挙げられ
る。これらのアクリレートは単独で、又は混合して用い
ることができる。
The terminal of the polypropyleneimine dendrimer, which is a polyfunctional amine compound, is modified with an alkyl-substituted acrylate derivative. As the alkyl-substituted acrylate derivative, a compound represented by the above formula (IV) is used. Here, n is 2 to 20, preferably 6
-20. Specific compounds include octadecyl acrylate, dodecyl acrylate, octadecyl methacrylate, dodecyl methacrylate, and the like. These acrylates can be used alone or as a mixture.

【0012】本発明のアルキル置換デンドリマーは、前
記多官能性アミン化合物とアルキル置換アクリル酸エス
テル誘導体を有機溶剤中で反応させることにより得られ
る。アクリル酸エステルの使用量は、多官能アミン[又
はポリ(プロピレンイミン)デンドリマー]1モルに対し
て、DAB−Am−8の場合は16〜80モル、好まし
くは16〜20モル、DAB−Am−4の場合は8〜4
0モル、好ましくは8〜10モル、またはアミノ基に対
して2〜10当量、好ましくは2〜2.5当量(Am−
8、Am−4のいずれに対しても)である。
The alkyl-substituted dendrimer of the present invention is obtained by reacting the polyfunctional amine compound with an alkyl-substituted acrylate derivative in an organic solvent. The amount of the acrylate used is 16 to 80 mol, preferably 16 to 20 mol, DAB-Am-, in the case of DAB-Am-8, relative to 1 mol of the polyfunctional amine [or poly (propylene imine) dendrimer]. 8 to 4 for 4
0 mol, preferably 8 to 10 mol, or 2 to 10 equivalents, more preferably 2 to 2.5 equivalents (Am-
8, and Am-4).

【0013】反応溶媒は、これらの溶媒として従来公知
のものがいずれも用いられてよい。具体的にはテトラク
ロロエチレン、1,2−ジクロロエタン、クロロホルム
などのハロゲン化炭化水素;アセトン、メチルエチルケ
トン、メチルイソブチルケトン、シクロヘキサノンなど
のケトン系溶媒;テトラヒドロフラン、ジオキサンなど
の環状エーテル系溶媒、トルエン、キシレンなどの芳香
族炭化水素系溶媒;N−メチル−2−ピロリドン、N,
N−ジメチルホルムアミド、N,N−ジメチルアセトア
ミド等の非プロトン性極性溶媒を用いることができる。
これらは単独で用いてもよく、また2種以上を混合して
用いてもよい。
As the reaction solvent, any of those conventionally known as these solvents may be used. Specifically, halogenated hydrocarbons such as tetrachloroethylene, 1,2-dichloroethane, and chloroform; ketone solvents such as acetone, methyl ethyl ketone, methyl isobutyl ketone, and cyclohexanone; cyclic ether solvents such as tetrahydrofuran and dioxane; and toluene and xylene Aromatic hydrocarbon solvents; N-methyl-2-pyrrolidone, N,
An aprotic polar solvent such as N-dimethylformamide and N, N-dimethylacetamide can be used.
These may be used alone or as a mixture of two or more.

【0014】反応温度は−50〜150℃、好ましくは
25〜80℃である。反応温度が−50℃未満であると
反応速度が著しく低下し好ましくない。また、150℃
を越える反応温度では、多官能性アミン化合物やアルキ
ル置換アクリル酸エステル誘導体の安定性の点で好まし
くない。
[0014] The reaction temperature is -50 to 150 ° C, preferably 25 to 80 ° C. If the reaction temperature is lower than −50 ° C., the reaction rate is remarkably reduced, which is not preferable. 150 ° C
If the reaction temperature exceeds, the stability of the polyfunctional amine compound or the alkyl-substituted acrylate derivative is not preferred.

【0015】反応時間は2〜200時間、好ましくは、
18〜90時間である。これより反応時間が短いと反応
が完全に進行せず好ましくない。反応終了後は溶剤を濃
縮して除去することにより、目的とするアルキル置換デ
ンドリマーを得ることができる。また、メタノール、エ
タノール、イソプロピルアルコール、ヘキサン、トルエ
ンなどの貧溶媒を加えて加熱し、上澄みを除去すること
により精製してもよい。
The reaction time is 2 to 200 hours, preferably
18-90 hours. If the reaction time is shorter than this, the reaction does not proceed completely, which is not preferable. After completion of the reaction, the target alkyl-substituted dendrimer can be obtained by concentrating and removing the solvent. Alternatively, purification may be performed by adding a poor solvent such as methanol, ethanol, isopropyl alcohol, hexane, and toluene, heating the mixture, and removing the supernatant.

【0016】[0016]

【実施例】本発明を実施例及び比較例によりさらに具体
的に説明する。合成はすべて窒素気流下で行った。な
お、得られたアルキル置換デンドリマーの特性は以下の
ようにして測定した。
The present invention will be described more specifically with reference to examples and comparative examples. All syntheses were performed under a stream of nitrogen. The properties of the resulting alkyl-substituted dendrimer were measured as follows.

【0017】 H NMR JNM−LA300(日本電子(株)製)を用いて測定し
た。IR FT/IR−230(日本分光(株)製)を用いて測定し
た。
[0017] 1 H NMR  Measured using JNM-LA300 (manufactured by JEOL Ltd.)
Was.IR  Measured using FT / IR-230 (manufactured by JASCO Corporation)
Was.

【0018】[実施例1] オクタデシル置換第1世代
プロピレンイミンデンドリマー(n=17)の合成 20mLの反応容器に、オクタデシルアクリレート(0.
88mmol,285.6mg)、ポリ(プロピレンイミ
ン)デンドリマーDAB−Am−4(0.10mmol,3
1.6mg)をとり、ジクロロメタン2.0mlを加え、
40℃で18時間攪拌した。室温まで冷却した後、この
溶液を激しく攪拌しながらトルエン中に滴下し、生成し
た沈殿を集めることにより目的物を精製した。これを減
圧乾燥し、結晶状の白色固体を収量151mg、収率5
2%で得た。HNMRによりアクリル二重結合の消費
(5.87,6.20,6.48ppm)とエステルのαおよ
びβ位のメチレン鎖の生成(2.47,2.75ppm)が
観測された。IRにより、1727.9cm−1(CO)
の特性吸収が観測された。
Example 1 Synthesis of Octadecyl-Substituted First-Generation Propyleneimine Dendrimer (n = 17) Octadecyl acrylate (0.1%) was placed in a 20 mL reaction vessel.
88 mmol, 285.6 mg), poly (propylene imine) dendrimer DAB-Am-4 (0.10 mmol, 3
1.6 mg), add 2.0 ml of dichloromethane,
Stirred at 40 ° C. for 18 hours. After cooling to room temperature, this solution was dropped into toluene with vigorous stirring, and the resulting precipitate was collected to purify the target product. This was dried under reduced pressure to give 151 mg of a crystalline white solid in a yield of 5 mg.
Obtained at 2%. Consumption of acrylic double bond by 1 HNMR
(5.87, 6.20, 6.48 ppm) and the formation of methylene chains at the α and β positions of the ester (2.47, 2.75 ppm) were observed. By IR, 1727.9 cm -1 (CO)
Characteristic absorption was observed.

【0019】[実施例2] オクタデシル置換第2世代
プロピレンイミンデンドリマー(n=17)の合成 オクタデシルアクリレートとポリ(プロピレンイミン)デ
ンドリマーDAB−Am−8を用い、実施例1と同様に
合成した。結晶状の白色固体を収量488mg、収率8
2%で得た。HNMRによりアクリル二重結合の消費
(5.87,6.20,6.48ppm)とエステルのαおよ
びβ位のメチレン鎖の生成(2.47,2.75ppm)が
観測された。IRにより、1727.8cm−1(CO)
の特性吸収が観測された。
Example 2 Synthesis of Octadecyl-Substituted Second-Generation Propyleneimine Dendrimer (n = 17) Synthesis was carried out in the same manner as in Example 1 using octadecylacrylate and poly (propyleneimine) dendrimer DAB-Am-8. 488 mg of a crystalline white solid was obtained in a yield of 8
Obtained at 2%. Consumption of acrylic double bond by 1 HNMR
(5.87, 6.20, 6.48 ppm) and the formation of methylene chains at the α and β positions of the ester (2.47, 2.75 ppm) were observed. By IR, 1727.8 cm -1 (CO)
Characteristic absorption was observed.

【0020】[0020]

【発明の効果】本発明の置換デンドリマーは両親媒性分
子であり、デンドリマー構造の特徴により相溶しない部
分構造間の位置関係が制限されるためにコーティング剤
としての機能が得られる。
As described above, the substituted dendrimer of the present invention is an amphipathic molecule, and the feature of the dendrimer structure restricts the positional relationship between the incompatible partial structures, and thus can function as a coating agent.

───────────────────────────────────────────────────── フロントページの続き Fターム(参考) 4H006 AA01 AA02 AB68 AB80 AB99 AC52 BB11 BB12 BB16 BB20 BB24 BB25 4H020 BA02  ──────────────────────────────────────────────────続 き Continued on the front page F term (reference) 4H006 AA01 AA02 AB68 AB80 AB99 AC52 BB11 BB12 BB16 BB20 BB24 BB25 4H020 BA02

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 下式: 【化1】 (式中、Rは、 【化2】 を意味し、nは2〜20の整数である。)で表されるア
ルキル置換デンドリマー。
1. The following formula: (Wherein R is And n is an integer of 2 to 20. An alkyl-substituted dendrimer represented by).
【請求項2】 下式: 【化3】 で表される多官能アミン化合物と下式: 【化4】 (式中、nは2〜20の整数を意味する。)で表されるア
ルキル置換アクリル酸エステル誘導体を、有機溶剤中に
て触媒の存在下または非存在下で反応させることを特徴
とする請求項1のアルキル置換デンドリマーの製造法。
2. The following formula: And a polyfunctional amine compound represented by the following formula: (Wherein n represents an integer of 2 to 20), wherein the alkyl-substituted acrylate derivative is reacted in an organic solvent in the presence or absence of a catalyst. Item 10. A process for producing an alkyl-substituted dendrimer according to item 1.
【請求項3】 下式: 【化5】 (式中、Rは、 【化6】 を意味し、nは2〜20の整数である。)で表されるア
ルキル置換デンドリマー。
3. The following formula: (Wherein R is And n is an integer of 2 to 20. An alkyl-substituted dendrimer represented by).
【請求項4】 下式: 【化7】 で表される多官能アミン化合物と下式: 【化8】 (式中、nは2〜20の整数を意味する。)で表されるア
ルキル置換アクリル酸エステル誘導体を、有機溶剤中に
て触媒存在下あるいは非存在下で反応させることを特徴
とするアルキル置換デンドリマーの製造法。
4. The following formula: And a polyfunctional amine compound represented by the following formula: (Wherein, n represents an integer of 2 to 20), wherein the alkyl-substituted acrylate derivative is reacted in an organic solvent in the presence or absence of a catalyst. Method for producing dendrimers.
JP2000366555A 2000-12-01 2000-12-01 Alkyl group-substituted dendrimer and method for preparing the same Pending JP2002167368A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2000366555A JP2002167368A (en) 2000-12-01 2000-12-01 Alkyl group-substituted dendrimer and method for preparing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000366555A JP2002167368A (en) 2000-12-01 2000-12-01 Alkyl group-substituted dendrimer and method for preparing the same

Publications (1)

Publication Number Publication Date
JP2002167368A true JP2002167368A (en) 2002-06-11

Family

ID=18837159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000366555A Pending JP2002167368A (en) 2000-12-01 2000-12-01 Alkyl group-substituted dendrimer and method for preparing the same

Country Status (1)

Country Link
JP (1) JP2002167368A (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008158492A (en) * 2006-12-21 2008-07-10 Samsung Electronics Co Ltd Spacer and liquid crystal display device having the same
JP2009501699A (en) * 2005-06-15 2009-01-22 マサチューセッツ インスティテュート オブ テクノロジー Amine-containing lipids and uses thereof
US8969353B2 (en) 2008-11-07 2015-03-03 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US9181321B2 (en) 2013-03-14 2015-11-10 Shire Human Genetic Therapies, Inc. CFTR mRNA compositions and related methods and uses
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US9227917B2 (en) 2012-08-13 2016-01-05 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US9308281B2 (en) 2011-06-08 2016-04-12 Shire Human Genetic Therapies, Inc. MRNA therapy for Fabry disease
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
US9522176B2 (en) 2013-10-22 2016-12-20 Shire Human Genetic Therapies, Inc. MRNA therapy for phenylketonuria
US9629804B2 (en) 2013-10-22 2017-04-25 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger RNA
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US9850269B2 (en) 2014-04-25 2017-12-26 Translate Bio, Inc. Methods for purification of messenger RNA
US9957499B2 (en) 2013-03-14 2018-05-01 Translate Bio, Inc. Methods for purification of messenger RNA
US10022455B2 (en) 2014-05-30 2018-07-17 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10138213B2 (en) 2014-06-24 2018-11-27 Translate Bio, Inc. Stereochemically enriched compositions for delivery of nucleic acids
US10576166B2 (en) 2009-12-01 2020-03-03 Translate Bio, Inc. Liver specific delivery of messenger RNA
US11173190B2 (en) 2017-05-16 2021-11-16 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
US11254936B2 (en) 2012-06-08 2022-02-22 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
US11253605B2 (en) 2017-02-27 2022-02-22 Translate Bio, Inc. Codon-optimized CFTR MRNA

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006487B2 (en) 2005-06-15 2015-04-14 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
JP2009501699A (en) * 2005-06-15 2009-01-22 マサチューセッツ インスティテュート オブ テクノロジー Amine-containing lipids and uses thereof
JP2008158492A (en) * 2006-12-21 2008-07-10 Samsung Electronics Co Ltd Spacer and liquid crystal display device having the same
US8969353B2 (en) 2008-11-07 2015-03-03 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US10844028B2 (en) 2008-11-07 2020-11-24 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US11414393B2 (en) 2008-11-07 2022-08-16 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US10189802B2 (en) 2008-11-07 2019-01-29 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US9556110B2 (en) 2008-11-07 2017-01-31 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US10576166B2 (en) 2009-12-01 2020-03-03 Translate Bio, Inc. Liver specific delivery of messenger RNA
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US10933139B2 (en) 2011-03-28 2021-03-02 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US10117934B2 (en) 2011-03-28 2018-11-06 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US10350303B1 (en) 2011-06-08 2019-07-16 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11338044B2 (en) 2011-06-08 2022-05-24 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11185595B2 (en) 2011-06-08 2021-11-30 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11951181B2 (en) 2011-06-08 2024-04-09 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11951179B2 (en) 2011-06-08 2024-04-09 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery
US10888626B2 (en) 2011-06-08 2021-01-12 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US9308281B2 (en) 2011-06-08 2016-04-12 Shire Human Genetic Therapies, Inc. MRNA therapy for Fabry disease
US11730825B2 (en) 2011-06-08 2023-08-22 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US9597413B2 (en) 2011-06-08 2017-03-21 Shire Human Genetic Therapies, Inc. Pulmonary delivery of mRNA
US10507249B2 (en) 2011-06-08 2019-12-17 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11547764B2 (en) 2011-06-08 2023-01-10 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery
US12121592B2 (en) 2011-06-08 2024-10-22 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US10413618B2 (en) 2011-06-08 2019-09-17 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US10238754B2 (en) 2011-06-08 2019-03-26 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery
US11052159B2 (en) 2011-06-08 2021-07-06 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11951180B2 (en) 2011-06-08 2024-04-09 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery
US11291734B2 (en) 2011-06-08 2022-04-05 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11254936B2 (en) 2012-06-08 2022-02-22 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
US9439968B2 (en) 2012-08-13 2016-09-13 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US9227917B2 (en) 2012-08-13 2016-01-05 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US11510937B2 (en) 2013-03-14 2022-11-29 Translate Bio, Inc. CFTR MRNA compositions and related methods and uses
US10420791B2 (en) 2013-03-14 2019-09-24 Translate Bio, Inc. CFTR MRNA compositions and related methods and uses
US11692189B2 (en) 2013-03-14 2023-07-04 Translate Bio, Inc. Methods for purification of messenger RNA
US11820977B2 (en) 2013-03-14 2023-11-21 Translate Bio, Inc. Methods for purification of messenger RNA
US10876104B2 (en) 2013-03-14 2020-12-29 Translate Bio, Inc. Methods for purification of messenger RNA
US9957499B2 (en) 2013-03-14 2018-05-01 Translate Bio, Inc. Methods for purification of messenger RNA
US9713626B2 (en) 2013-03-14 2017-07-25 Rana Therapeutics, Inc. CFTR mRNA compositions and related methods and uses
US9181321B2 (en) 2013-03-14 2015-11-10 Shire Human Genetic Therapies, Inc. CFTR mRNA compositions and related methods and uses
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
US10493031B2 (en) 2013-10-22 2019-12-03 Translate Bio, Inc. Lipid formulations for delivery of messenger RNA
US10052284B2 (en) 2013-10-22 2018-08-21 Translate Bio, Inc. Lipid formulations for delivery of messenger RNA
US10959953B2 (en) 2013-10-22 2021-03-30 Translate Bio, Inc. Lipid formulations for delivery of messenger RNA
US9522176B2 (en) 2013-10-22 2016-12-20 Shire Human Genetic Therapies, Inc. MRNA therapy for phenylketonuria
US11377642B2 (en) 2013-10-22 2022-07-05 Translate Bio, Inc. mRNA therapy for phenylketonuria
US9629804B2 (en) 2013-10-22 2017-04-25 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger RNA
US10208295B2 (en) 2013-10-22 2019-02-19 Translate Bio, Inc. MRNA therapy for phenylketonuria
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
US11890377B2 (en) 2013-10-22 2024-02-06 Translate Bio, Inc. Lipid formulations for delivery of messenger RNA
US11884692B2 (en) 2014-04-25 2024-01-30 Translate Bio, Inc. Methods for purification of messenger RNA
US9850269B2 (en) 2014-04-25 2017-12-26 Translate Bio, Inc. Methods for purification of messenger RNA
US10155785B2 (en) 2014-04-25 2018-12-18 Translate Bio, Inc. Methods for purification of messenger RNA
US12060381B2 (en) 2014-04-25 2024-08-13 Translate Bio, Inc. Methods for purification of messenger RNA
US11059841B2 (en) 2014-04-25 2021-07-13 Translate Bio, Inc. Methods for purification of messenger RNA
US10286082B2 (en) 2014-05-30 2019-05-14 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10493166B2 (en) 2014-05-30 2019-12-03 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10286083B2 (en) 2014-05-30 2019-05-14 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10912844B2 (en) 2014-05-30 2021-02-09 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10293057B2 (en) 2014-05-30 2019-05-21 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10022455B2 (en) 2014-05-30 2018-07-17 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US11433144B2 (en) 2014-05-30 2022-09-06 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10138213B2 (en) 2014-06-24 2018-11-27 Translate Bio, Inc. Stereochemically enriched compositions for delivery of nucleic acids
US11104652B2 (en) 2014-06-24 2021-08-31 Translate Bio, Inc. Stereochemically enriched compositions for delivery of nucleic acids
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US11253605B2 (en) 2017-02-27 2022-02-22 Translate Bio, Inc. Codon-optimized CFTR MRNA
US11173190B2 (en) 2017-05-16 2021-11-16 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
US12084702B2 (en) 2018-08-24 2024-09-10 Translate Bio, Inc. Methods for purification of messenger RNA

Similar Documents

Publication Publication Date Title
JP2002167368A (en) Alkyl group-substituted dendrimer and method for preparing the same
US20090069561A1 (en) Click chemistry route to triazole dendrimers
US20180009788A1 (en) Bisphenols containing pendant clickable maleimide group and polymers therefrom
CN114409890A (en) Amino-functionalized polyethylene glycol derivative and preparation method thereof
KR20110094311A (en) Method for preparing activated esters
JP2005524401A5 (en)
JP2002167370A (en) Alkylazobenzene-substituted dendrimer and method for preparing the same
CN1953963B (en) Process for producing cyclic N-hydroxyimide compound
CN114989337B (en) Polymer with valine and mannose in side chains and preparation method thereof
JP2008056894A (en) Hyperbranched polymer and production method thereof, as well as monomer for synthesizing hyperbranched polymer and precursor thereof
CN114479059B (en) Propionaldehyde functionalized polyethylene glycol derivative and preparation method thereof
CN113717085B (en) Accurate-sequence poly-monothioacetal and preparation method thereof
CN115197232A (en) Cyclopropane fused oxygen bridge hexacyclic compound and synthesis method thereof
CN109574866B (en) Preparation method of 2, 6-dimethylaniline long-chain compound
JP2002338535A (en) Polyhydroxy dendrimer and method for producing the same
JP2002322273A (en) Cholesteric liquid crystalline dendrimer and method for producing the same
JP2001163971A (en) Alkoxymethyl ester dendrimer and production method thereof
JP2001172385A (en) Liquid-crystalline dendrimer and production method therefor
JP3697045B2 (en) Process for producing β-hydrazino esters and pyrazolidinones, pyrazolones and β-amino acid derivatives
KR102605275B1 (en) Amide heptamer and method for preparing thereof
WO2020195889A1 (en) Pyrrole imidazole poly(amide) production method
JP2009185125A (en) Hyperbranched polymer, method for producing the same, monomer for synthesizing hyperbranched polymer, and precursor thereof
CN113354562A (en) Brush polymer with highly ordered side chain arrangement and preparation method and application thereof
EP1063227A1 (en) Hydrazide fixed to resin and derivative thereof, and method for synthesizing pyrazolones in solid phase
JP2000264965A (en) Liquid crystalline dendrimer and its production